A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

NCT02234986 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CASI pharmaceuticals, Inc.